NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Incyte Corporation (INCY) Stock Analysis

Incyte Corporation (INCY) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

INCY

$113.44

−$3.17 (−2.72%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare INCY with… →

INCY Key Statistics

As of Oct 21, 2026
Trading
Open
$115.98
Previous Close
$116.62
Day's Range
113.35–116.57
52-Week Range
84.02–132.60
Volume
1.39M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.74
Valuation
Market Cap
$22.99B
P/E Ratio
14.45
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
13.07
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
10.82
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.95
EPS (ttm)Profit attributable to each share over the last twelve months.
7.85
Financials (FY)
Revenue (FY)
$5.14B+21.22%
Net Income (FY)
$1.29B+3,844.96%
Profit marginThe share of revenue left as profit after all costs and taxes.
27.71%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
202.70M
1-Year Return
+29.94%
Dividend and dates
Earnings Date
October 29, 2026
Avg Volume
1.63M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, INCY closed at $113.44, +29.94% over 1 year.

Incyte Corporation (INCY) has a market capitalization of $22.99B.

In fiscal 2025, INCY reported revenue of $5.14B.

INCY Stock Return by Calendar Year

Incyte Corporation (INCY) 10-year return: what $10,000 became

1 year
$10,000 $12,994
+29.94%
5 years
$10,000 $17,222
+72.22%
10 years
$10,000 $12,932
+29.32%

If you had invested $10,000 in Incyte Corporation (INCY) 10 years ago, at the close on October 21, 2016, it would have been worth $12,932 at the close on October 21, 2026: +29.32% in total, +2.60% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+14.85%
2025+43.00%
2024+10.00%
2023−21.83%
2022+9.43%
2021−15.61%
2020−0.39%
2019+37.32%
2018−32.86%
2017−5.55%
2016 (partial year)+13.89%

As of October 21, 2026.

INCY Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$5.14B$1.29B25.0%
2024$4.24B$32.62M0.8%
2023$3.70B$597.60M16.2%
2022$3.39B$340.66M10.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$5.14B$4.77B$1.34B$1.29B25.0%
2024$4.24B$3.93B$101.29M$32.62M0.8%
2023$3.70B$3.44B$655.36M$597.60M16.2%
2022$3.39B$3.19B$591.63M$340.66M10.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

INCY Valuation vs Biotechnology Median

Median of 608 stocks
MetricINCYBiotechnology medianvs median
P/E14.4516.6013% below
P/S ratio3.9513.300.3x the median
Profit margin27.71%−38.31%66.0 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Incyte Corporation (INCY) is capitalised at $22.99B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 2,844.

Over the past 52 weeks the price has ranged from $84.02 to $132.60. The most recent close on file for INCY is $113.44, dated October 21, 2026. That is −$3.17 (−2.72%) against the previous close. The latest close sits 35.02% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $5.14B. That is +21.22% against the prior fiscal year, when revenue was $4.24B. Net income for the same year was $1.29B. That is +3,844.96% against the prior fiscal year. The reported profit margin is 27.71%. That is 66 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are 7.85.

Across the 4 fiscal years on file, revenue moves from $3.39B in 2022 to $5.14B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

INCY trades at a trailing price-to-earnings ratio of 14.45. That is 12.95% below the Biotechnology median of 16.6. The forward P/E on file is 13.07. The PEG ratio, which sets the P/E against expected earnings growth, reads 10.82. Measured against sales, the shares trade at 3.95 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is +29.94%. Measured over 10 years, that is +2.60% a year compounded. The reported beta is 0.74. Annualized volatility over the trailing 10 years is 34.19%.

Growth & Income

No dividend is on file for INCY.

So far in 2026 the total return is +14.85%. The strongest complete calendar year on file is 2025 at +43.00%; the weakest is 2018 at −32.86%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Incyte Corporation (INCY) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Incyte Corporation INCY $22.99B 14.5
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Incyte Corporation trades at a P/E of 14.5.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Incyte Corporation

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Visit website →